LV V-Haemorphin-7 neuroactive peptide and methods of use

Details LV V-Haemorphin-7 neuroactive peptide and methods of use LV V-Haemorphin-7 neuroactive peptide and methods of use

2006-04-11

2006-04-11

Andres, Janet L. (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C530S350000

Reexamination Certificate

active

07026280

ABSTRACT:
The invention relates to neuroactive peptides or analogues thereof, having at least one of the biological activities of angiotensin IV, and which comprise the sequence Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe, to methods of modulating neuronal activity, and to pharmaceutical composition thereof.

REFERENCES:
patent: 5063206 (1991-11-01), Bridge et al.
patent: 5599907 (1997-02-01), Anderson et al.
patent: 5861483 (1999-01-01), Wolpe et al.
Kandel et al., Principles in Neural Science, Elsevier, 1991, pp. 1056-1057.
Wilkinson et al., Neurosurgery, Apr. 1994, 34(4):665-68.
Relton et al., J. of Exp. Med., Aug. 1991, 174(2):305-10.
Furey, et al, 1997, Proc. Natl. Acad. Sci., 94: 6512-6516.
Peng, et al, 1997, Jpn. J. Pharmacol., 74: 261-266.
Neurobiology of Disease, 1990, Pearlman and Collins, eds, Oxford, pp. 306-308.
Gallagher & Rapp, 1997, Annual Review of Psychology, vol. 48, pp. 339-370.
Molchan, et al, 1992, Brain Res. Rev., 17: 215-226.
Blokland, et al, 1995, Brain Res Rev., 21(3):285-300.
Davies P, & Maloney A, 1976, Lancet, Letters to the Editor, p. 1403.
Naveen & Kohli, 2003, Indian Journal of Pharmacology, 35: 104-108.
Ye, et al, 1999, Journal of Pharmacol. Exp Ther; 288(2): 814-819.
Ebert & Kirch, 1998, European Journal of Clinical Investigation, vol. 28 Issue 11, p. 944.
Lee, et al, 2003, J. Pharmacol. Exp. Therap, 305: 205-211.
I. Moeller et al, “The Globin Fragement LVV-Hemorphin-7 is an Endogenous Ligand for the AT4Receptor in the Brian”, Journal of Neurochemistry vol. 68, No. 6, Jun. 1997, pp 2530-2537.
I. Garreau et al, “VV-hemorphin-7 and LVV-hemorphin-7 Released during in vitro Peptic hemoglobin Hydrolysis are Morphinomimetic Peptides”, Neuropeptides, vol. 28, 1995, pp. 243-250.
J. Piot, et al, “Isolation and Characterization of Two Opiod Peptides from a Bovine Hemoglobin Peptic Hydrolysate”, Biochemical and Biophysical Research Communications, vol. 189, No. 1, Nov. 1992, pp. 101-110.
E. Giamsta et al, “Isolation of a Hemoglobin-Derived Opiod Peptide from Cerebrospinal Fluid of Patients with Cerebrovascular Bleedings”, Biochemical and Biophysical Research Communications, vol. 184, No. 2, Apr. 30, 1992, pp. 1060-1066.
R. Chang et al, “Isolation and Structure of Several Peptides from Porcine Hypothalami”, Biochimica et Biophysica Acta, 1980, vol. 625, pp. 266-273.
J. Szikra et al, “Receptor Binding Properties of a Hemorphin Analogue in Rat Brain Membrane Preparations”, Neurobiology, vol. 4, 1996, pp. 279-280.
A. Karelin, et al, “Isolation of Endogenous Hemorphin-Related Hemoglobin Fragments from Bovine Brain”, vol. 22, No. 1, Jul. 15, 1994, pp. 410-415.
C. Woo et al, “cDNA Sequences of Two β-Globin Genes in Sprague-Dawley Rat”, Nucleic Acids Research, vol. 17, No. 21, 1989, pp. 8870.

Affiliated with

Also associated with

Rating

LV V-Haemorphin-7 neuroactive peptide and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with LV V-Haemorphin-7 neuroactive peptide and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LV V-Haemorphin-7 neuroactive peptide and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3548469